N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
Version 2 2024-06-06, 07:50Version 2 2024-06-06, 07:50
Version 1 2022-03-23, 08:35Version 1 2022-03-23, 08:35
journal contribution
posted on 2024-06-06, 07:50authored byJ Sarris, G Byrne, D Castle, C Bousman, G Oliver, L Cribb, S Blair-West, V Brakoulias, D Camfield, C Ee, S Chamoli, M Boschen, Olivia DeanOlivia Dean, N Dowling, R Menon, J Murphy, NJ Metri, TP Nguyen, A Wong, R Jordan, D Karamacoska, SL Rossell, Michael BerkMichael Berk, CH Ng
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
History
Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry